Overview

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)